This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Proteostasis Therapeutics (PTI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Proteostasis (PTI) delivered earnings and revenue surprises of -11.43% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Proteostasis Therapeutics (PTI) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Proteostasis (PTI) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.
Vertex Selects Triple Combo Regimen for Regulatory Submission
by Zacks Equity Research
Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
Proteostasis Therapeutics (PTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Proteostasis (PTI) delivered earnings and revenue surprises of 34.88% and 525.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
Analysts Estimate Proteostasis Therapeutics (PTI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
by Zacks Equity Research
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.
Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
by Zacks Equity Research
Proteostasis Therapeutics (PTI) needs investors to pay close attention to the stock based on moves in the options market lately.
This Week's Top Tech Earnings and Today's Trending Stocks: PTI & NBEV
by Ryan McQueeney
Ryan McQueeney discusses concerns about slowing economic growth in China and a major court ruling affecting healthcare stocks. He also highlights trending stocks Proteostasis Therapeutics and New Age Beverages. Later, he previews earnings from Red Hat, Oracle, and Micron.
Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.
Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.
Proteostasis Therapeutics (PTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Proteostasis (PTI) delivered earnings and revenue surprises of -8.70% and 27.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Proteostasis Therapeutics (PTI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.
Proteostasis Therapeutics (PTI) Enters Oversold Territory
by Zacks Equity Research
Proteostasis Therapeutics, Inc. (PTI) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?
by Zacks Equity Research
Investors in Proteostasis Therapeutics (PTI) need to pay close attention to the stock based on moves in the options market lately.
Proteostasis Therapeutics (PTI) Looks Good: Stock Adds 8% in Session
by Zacks Equity Research
Proteostasis Therapeutics (PTI) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.
Proteostasis Stock Surges on Positive Data From CF Studies
by Zacks Equity Research
Proteostasis (PTI) stock skyrockets on positive results from early and mid-stage studies on its cystic fibrosis pipeline candidates.
GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.
Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) is scheduled to report first-quarter 2017 results on May 5, before the opening bell.
Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
We expect Conatus Pharmaceuticals Inc. (CNAT) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
What's in the Cards for Ecolab (ECL) this Earnings Season?
by Zacks Equity Research
Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report first-quarter 2017 results on May 2.